| KISS, David, Táňa MACHÁČKOVÁ, Kamila SOUČKOVÁ, Pavel FABIAN, I. KREPELKOVA, M. SVOBODA and Igor KISS. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2021, vol. 35, No 5, p. 2809-2814. ISSN 0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12567. |
Other formats:
BibTeX
LaTeX
RIS
@article{1837296,
author = {Kiss, David and Macháčková, Táňa and Součková, Kamila and Fabian, Pavel and Krepelkova, I. and Svoboda, M. and Kiss, Igor},
article_location = {ATHENS},
article_number = {5},
doi = {http://dx.doi.org/10.21873/invivo.12567},
keywords = {Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation},
language = {eng},
issn = {0258-851X},
journal = {In vivo},
title = {An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer},
url = {https://iv.iiarjournals.org/content/35/5/2809},
volume = {35},
year = {2021}
}
TY - JOUR
ID - 1837296
AU - Kiss, David - Macháčková, Táňa - Součková, Kamila - Fabian, Pavel - Krepelkova, I. - Svoboda, M. - Kiss, Igor
PY - 2021
TI - An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer
JF - In vivo
VL - 35
IS - 5
SP - 2809-2814
EP - 2809-2814
PB - Greece : International Institute of Anticancer Research
SN - 0258851X
KW - Bevacizumab
KW - metastatic colorectal cancer
KW - microRNA
KW - progression-free survival
KW - predictive biomarker
KW - validation
UR - https://iv.iiarjournals.org/content/35/5/2809
N2 - Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival
ER -
KISS, David, Táňa MACHÁČKOVÁ, Kamila SOUČKOVÁ, Pavel FABIAN, I. KREPELKOVA, M. SVOBODA and Igor KISS. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2021, vol.~35, No~5, p.~2809-2814. ISSN~0258-851X. Available from: https://dx.doi.org/10.21873/invivo.12567.
|
